Currently there is an increase in the emergence and re-emergence of bacterial infections, and lichens are potential sources of pharmaceutically important secondary metabolites to halt this problem. Lichens are unique plant-like organisms which are relatively less explored in the Philippines. Here, lichen extracts of Leptogium cochleatum and Leptogium moluccanum were tested against Escherichia coli, Enterobacter agglomerans, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus using paper disk diffusion assay. Hexane extract of L. moluccanum led to a 17.14 mm zone of inhibition (ZOI) against K. pneumoniae, while hexane extract of L. cochleatum led to a 15.28 mm ZOI against E. agglomerans. Dichloromethane extracts of L. cochleatum exhibited a ZOI of 15.86 mm against E. agglomerans and 14.84 mm ZOI against E. coli. The bioactivities exhibited by the lichen extracts may be due to the secondary metabolites detected using thin layer chromatography. Indeed, lichen-derived bioactive compounds hold great promise for pharmaceutical applications for the benefit of human life. Keywords: Antibacterial activity, Crude extracts, Lichen, Secondary metabolites, Thin-layer chromatography, Zone of inhibition.